Talvey access in the UAE: the EDE named-patient pathway

How UAE patients with relapsed or refractory multiple myeloma access Talvey (talquetamab-tgvs), the first-in-class GPRC5D-directed bispecific antibody, when the locally available treatment ladder has been exhausted and the haematology team is sourcing a step-up dosing course from US-licensed supply.

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Talvey (talquetamab-tgvs) is a bispecific antibody that engages G protein-coupled receptor family C group 5 member D (GPRC5D) on myeloma cells and CD3 on T cells. It was granted accelerated approval by the US FDA on 9 August 2023 for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. GPRC5D is highly expressed on malignant plasma cells with only limited expression on healthy tissue (tongue keratinocytes, hair follicles, nail beds, skin), which translates to the on-target adverse event signature unique to this drug. Talvey is not registered in the UAE; every UAE myeloma family that uses talquetamab does so through the EDE named-patient pathway. Reserve Meds coordinates the US-side sourcing, the cold-chain logistics, the documentation packet your physician needs, and the inpatient step-up window where Janssen's REMS-equivalent protocol expects monitoring.

Reserved for you.

Why UAE patients need Talvey through the named-patient pathway

Talquetamab fills a defined slot in the UAE myeloma access map. Patients reach the GPRC5D bispecific conversation in one of three patterns. First, post-CAR-T relapse. A patient who has had cilta-cel or ide-cel and progressed needs an off-the-shelf option that targets a different antigen; GPRC5D versus BCMA is the cleanest mechanism-of-action switch available, and the MonumenTAL-1 trial showed an overall response rate of approximately 73 percent in BCMA-naive patients and approximately 64 percent in patients previously exposed to BCMA-targeted therapy including bispecifics and CAR-T. Second, BCMA-bispecific intolerance or progression. Teclistamab (Tecvayli) and elranatamab (Elrexfio) are the BCMA bispecifics; a patient who progressed on or could not tolerate either has talquetamab as the next bispecific option. Third, fifth-line-or-later relapse where the standard lines (bortezomib, lenalidomide, daratumumab, carfilzomib, pomalidomide, isatuximab, selinexor) have been exhausted and CAR-T is not feasible or available in the timeline disease progression allows.

In each of those three patterns, talquetamab is not stocked on the UAE register and the EDE named-patient pathway is the lawful route to bring US-labelled product to a UAE-licensed haematologist's prescription. Tertiary haematology services at Cleveland Clinic Abu Dhabi, Sheikh Khalifa Medical City, Tawam Hospital, American Hospital Dubai, King's College Hospital London Dubai, and Mediclinic City Hospital handle myeloma to international standards through induction, transplant, and maintenance, and they reach for novel-mechanism off-shelf bispecifics when the relapsed disease no longer responds to the standard ladder. The EDE pathway is the regulatory mechanism that makes the prescription operationally possible.

The EDE named-patient pathway for Talvey

The federal pathway for a UAE-licensed physician to obtain a medicine not registered or stocked locally is the unregistered-medicine import permit, historically administered by MOHAP and, from 29 December 2025, administered through the Emirates Drug Establishment portal at ede.gov.ae under Federal Decree-Law No. 38 of 2024. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. For Talvey, the reference-authority test is met cleanly: FDA accelerated approval 9 August 2023 (BLA 761342) and EMA conditional marketing authorisation 22 August 2023.

A complete application includes a clinical justification letter from the treating haematologist (diagnosis, ISS or R-ISS staging, cytogenetics, prior lines of therapy with response and duration, current disease status, rationale for GPRC5D-directed bispecific specifically rather than the BCMA class, and the proposed step-up and maintenance schedule), the haematologist's UAE medical license verification (MOHAP, DHA, DOH Abu Dhabi, or Sharjah Health Authority depending on practice location), an anonymised patient identifier where the EDE submission allows, full product details (brand Talvey, generic talquetamab-tgvs, manufacturer Janssen Biotech, strength 3 mg/1.5 mL or 40 mg/1.0 mL single-dose vials, lot, expiry, requested quantity), the destination dispensing facility name, license number, and pharmacy in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy under cold-chain conditions.

The clinical justification angle in a Talvey EDE file typically anchors on one of two patterns. For a post-CAR-T relapse case, the prescriber documents the prior cilta-cel or ide-cel course, the duration of response, the time to progression, the current disease status, and the rationale for switching to GPRC5D after BCMA-directed therapy has failed. For a fifth-line-or-later relapse case with no prior CAR-T, the prescriber documents the four prior lines (proteasome inhibitor, immunomodulatory agent, anti-CD38 antibody, and either bispecific or other class member) with response and duration, the current disease status, and the rationale for talquetamab as the GPRC5D off-shelf option versus the BCMA bispecifics, where appropriate.

Approval timelines for cell-engaging biologic cases are typically 10 to 21 business days through EDE review for routine files; complex cases or first-import requests for a given product extend to 6 to 8 weeks. The EDE retains discretion on timing and we do not promise specific durations.

Where Talvey gets dispensed in the UAE

Talvey is a refrigerated biologic administered subcutaneously, with a step-up dosing schedule that requires inpatient monitoring during the first two or three doses for cytokine release syndrome and neurotoxicity surveillance per the Janssen risk evaluation framework that mirrors the US REMS requirements. The dispensing facility list narrows from the full UAE specialty hospital network to those institutions with validated 2 to 8 degree Celsius pharmacy storage, an inpatient haematology service line with CRS and ICANS management protocols, and physicians experienced with the bispecific antibody step-up workflow. In practice that includes Cleveland Clinic Abu Dhabi on Al Maryah Island (an M42 group hospital with a tertiary haematology and oncology service line and ICU backup), Sheikh Khalifa Medical City in Abu Dhabi (a SEHA-network 586-bed JCI-accredited hospital), Tawam Hospital in Al Ain (a SEHA-network oncology referral centre), American Hospital Dubai (a Mayo Clinic Care Network member with a haematology-oncology service line), King's College Hospital London Dubai, and Mediclinic City Hospital in Dubai Healthcare City.

The step-up dosing schedule for the weekly regimen consists of step-up dose 1 of 0.01 mg/kg subcutaneously, step-up dose 2 of 0.06 mg/kg subcutaneously 2 to 4 days later, and the first treatment dose of 0.4 mg/kg subcutaneously 2 to 4 days after that, followed by 0.4 mg/kg weekly thereafter. The biweekly regimen uses three step-up doses (0.01, 0.06, 0.32 mg/kg) before the first treatment dose of 0.8 mg/kg every two weeks. Each step-up dose and the first treatment dose require 48-hour inpatient or close-observation monitoring per Janssen protocol because cytokine release syndrome (incidence approximately 76 percent in MonumenTAL-1, predominantly grade 1 or 2) and immune effector cell-associated neurotoxicity syndrome (approximately 10 to 14 percent) cluster in the step-up window. The dispensing pharmacy releases the doses to the inpatient ward during step-up and to the outpatient infusion or self-administration arm once the patient is on weekly or biweekly maintenance.

Real cost picture for Talvey in the UAE

US wholesale acquisition cost for Talvey is approximately USD 25,000 per month at the maintenance dosing for an average-weight adult, per Janssen published pricing and ASP reporting. Per-vial pricing on the 40 mg/1.0 mL vial sits at approximately USD 7,950 per vial and the 3 mg/1.5 mL vial at approximately USD 596 per vial, with monthly cost driven by the weekly versus biweekly schedule, the patient's weight, and the number of doses per month. The UAE dirham is pegged to the US dollar at approximately 3.67 AED to 1 USD, so the monthly reference range converts to roughly AED 91,000 to AED 110,000 at US WAC equivalents. The step-up window (first three doses across approximately one to two weeks) carries lower drug cost because step-up doses are subtherapeutic; the cumulative drug cost concentrates in the maintenance phase.

International logistics for a cold-chain biologic shipment to the UAE typically runs USD 400 to USD 1,500 (approximately AED 1,500 to AED 5,500) per shipment depending on destination emirate, urgency, and consolidated supply window. UAE customs and EDE permit fees are nominal relative to drug cost. Reserve Meds itemises the drug cost, the logistics, and the concierge coordination fee separately on every firm quote. The bulk of the patient's all-in cost over a 6 to 12 month treatment course is the drug itself; the inpatient step-up monitoring fees at the dispensing UAE hospital are billed by that hospital and are not part of the Reserve Meds quote.

On the insurance side, UAE private insurers including Daman, GIG Gulf, Sukoon, ADNIC, and Orient handle myeloma bispecific named-patient imports case by case with prior authorisation. Thiqa, the government-funded programme for UAE nationals administered by Daman, has the broadest specialty coverage in Abu Dhabi. We do not promise coverage from any insurer; cash-pay is the default operating posture and reimbursement is pursued in parallel where the policy permits.

Typical timeline for Talvey in the UAE

From waitlist submission to first step-up dose, the typical Talvey case in the UAE runs as follows. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to the treating haematologist. The physician or hospital import pharmacy or EDE-licensed importer files the unregistered-medicine application, which clears in 10 to 21 business days for routine cases. In parallel, Reserve Meds aligns US-side specialty pharmacy sourcing, validated cold-chain qualification, and the shipment plan. Once EDE approval is issued, US release and shipment add 5 to 10 business days for cold-chain transit plus customs clearance into the importer's bonded warehouse or directly to the hospital. The step-up admission is scheduled at the dispensing hospital, typically a 5 to 7 day inpatient window for the two or three step-up doses and the first treatment dose. The full cycle from waitlist to first treatment dose is typically 4 to 6 weeks. Re-supply on the weekly or biweekly cadence is then planned in 8 to 12 week shipment windows.

What your physician needs to provide

The clinical justification letter is the cornerstone of the EDE package for Talvey. On institutional letterhead, signed by a UAE-licensed haematologist, the letter typically documents the multiple myeloma diagnosis with ISS or R-ISS staging and baseline cytogenetics, the prior treatment history (regimen, duration, best response, reason for discontinuation for each line), the current disease status with M-protein, light-chain, bone marrow plasma cell percentage, and imaging summary, the rationale for GPRC5D-directed therapy specifically rather than BCMA-directed bispecific or CAR-T (post-CAR-T relapse, BCMA-bispecific failure or intolerance, or fifth-line-or-later relapse with mechanism-of-action diversification), the proposed step-up and maintenance schedule (weekly 0.4 mg/kg or biweekly 0.8 mg/kg after step-up), and the monitoring plan covering cytokine release syndrome and neurotoxicity with tocilizumab and supportive care protocols available at the dispensing facility.

The letter also addresses the GPRC5D-class-specific adverse events that distinguish Talvey from BCMA bispecifics: dysgeusia (approximately 72 percent of patients, generally grade 1 or 2 but persistent and clinically meaningful for nutrition and quality of life), nail toxicity (approximately 56 percent), skin disorders including rash and xerosis (approximately 67 percent), and weight decrease (approximately 41 percent). The monitoring plan should describe the nutrition support pathway, the dental and ENT input where dysgeusia is severe, and the dermatology and podiatry consults that often accompany the GPRC5D adverse event cluster. Infectious disease monitoring follows the broader bispecific class profile: hepatitis B screening at baseline, CMV monitoring during therapy, and IVIG support if hypogammaglobulinaemia develops.

The treating physician's UAE medical license verification, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. The hospital protocols for the 48-hour inpatient monitoring window after each step-up dose and the first treatment dose are confirmed in writing so EDE has clear evidence the dispensing facility can manage the early-cycle safety window.

Common questions about Talvey in the UAE

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover Talvey? Each insurer assesses bispecific named-patient imports case by case with prior authorisation and typically with significant patient coinsurance. Thiqa has the broadest specialty coverage for UAE nationals in Abu Dhabi. We supply the documentation set the insurer needs; the claim itself sits with you or your hospital.

How does Talvey compare to Tecvayli or Elrexfio? Tecvayli (teclistamab) and Elrexfio (elranatamab) are BCMA-directed bispecifics; Talvey is the GPRC5D-directed bispecific. Mechanism-of-action diversification matters when a patient has progressed on BCMA-directed therapy (CAR-T or bispecific). The GPRC5D class shows distinct adverse event signatures, particularly dysgeusia, nail and skin toxicity, and weight loss, which are largely absent from the BCMA class. The choice between the bispecifics is a haematology team decision based on prior therapy, current disease, and patient-specific tolerance considerations. Reserve Meds does not promote one over another; the EDE pathway supports the prescription written. See our dedicated pages on Tecvayli in the UAE and Carvykti in the UAE.

What about the dysgeusia and skin and nail adverse events? The GPRC5D target is expressed on tongue keratinocytes, hair follicles, nail beds, and skin in addition to malignant plasma cells. Dysgeusia (taste alteration or loss), nail dystrophy, hair changes, and rash are the on-target consequences. These are largely grade 1 or 2 but can be persistent and clinically meaningful for quality of life. The nutrition support team and dermatology consult become important parts of the care plan; dose interruption or schedule modification (typically to biweekly dosing) may improve tolerance.

Can Talvey be self-administered at home after the step-up? The maintenance subcutaneous doses can be administered in an outpatient infusion suite or, in some centres after several maintenance doses without CRS or ICANS events, at home with appropriate training and a caregiver present. The first treatment dose and any dose escalations are inpatient or close-observation per Janssen protocol. The dispensing UAE hospital determines the transition point to outpatient or home administration on a patient-by-patient basis.

What about pre-medication? Pre-medication with a corticosteroid, an antihistamine, and an antipyretic is required at each step-up dose and the first treatment dose to mitigate cytokine release syndrome. The exact regimen mirrors the BCMA bispecific protocol and is administered approximately 1 to 3 hours before each dose. Subsequent maintenance doses may not require pre-medication if the patient has tolerated prior doses without CRS, per the Janssen prescribing information.

What is the duration of therapy? Talvey is administered until disease progression or unacceptable toxicity. The MonumenTAL-1 median duration of response was approximately 9 to 12 months in the BCMA-naive cohort. Some centres consider dose holidays or schedule de-intensification after a sustained response, particularly if dysgeusia or skin adverse events drive quality-of-life concerns; the Janssen prescribing information does not formally support fixed-duration therapy.

What about hepatitis B reactivation? Bispecific antibody therapy in myeloma carries hepatitis B reactivation risk, and the Janssen prescribing information requires hepatitis B screening at baseline and antiviral prophylaxis where indicated. The treating UAE physician documents the screening at baseline and prescribes prophylaxis per current guidelines.

Where Reserve Meds fits in Talvey cases

Reserve Meds is a US-based concierge coordinator. We do not replace your haematologist, we do not replace the EDE, and we do not replace your dispensing pharmacy. For Talvey specifically, we orchestrate US-side sourcing through a DSCSA-compliant specialty channel, build the EDE documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the UAE, and assign a single named coordinator through the step-up admission, the maintenance shipment cadence, and the continuity-of-supply window. Bispecific antibody coordination is a defining concierge case for Reserve Meds because the step-up monitoring, the maintenance shipment cadence, and the supportive care framework all sit at the intersection of US sourcing, UAE regulatory documentation, and dispensing-facility logistics. No prior Reserve Meds dispensed-case experience as of this page; standard NPP coordination under our cold-chain biologic and step-up bispecific playbook applies.

Next step

If your UAE haematologist has prescribed Talvey and the family is weighing the cross-border named-patient route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send the documentation kit to your physician.

Add my UAE Talvey case to the waitlist